AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise Medical Dialogues Bureau10 May 2019 9:00 AM ISTThe treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic...
Hetero launches generic Lapatinib under the brand name HERTAB in India Farhat Nasim12 Jan 2019 12:14 PM ISTHERTAB (Lapatinib) is an oral therapy indicated for the treatment of postmenopausal women with HER2-positive advanced breast cancer patients whose...
EMA accepts marketing authorization applications of Mylan and Biocon for 2 biosimilars Ruby Khatun Khatun2 Dec 2017 10:00 AM ISTHERTFORDSHIRE, England, PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the European Medicines Agency (EMA) has accepted for...
Roche Perjeta regimen gets FDA priority review in breast cancer Ruby Khatun Khatun4 Oct 2017 9:20 AM ISTZURICH: The U.S. Food and Drug Administration (FDA) has granted a priority review for Roche's Perjeta in combination with Herceptin and chemotherapy...